Evidence map›Paper›PMID 18613829›Full record

ReviewImmunological reviews2008

How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets.

Virginia Pascual, Florence Allantaz, Pinakeen Patel, A Karolina Palucka, Damien Chaussabel, Jacques Banchereau

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Immunological reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01780857 (The Immune Signature of Palmoplantar Pustulosis), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01780857 completednot on this mapstarted 2013, after this paper: background citation

The Immune Signature of Palmoplantar Pustulosis

TypeobservationalSponsorBaylor Research InstituteRan2013 to 2014Enrolled30ConditionsPalmoplantar Pustulosis
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Virginia PascualBaylor Institute for Immunology Research and Baylor Research Institute, Dallas, TX 75204, USA.
Florence Allantaz
Pinakeen Patel
A Karolina Palucka
Damien Chaussabel
Jacques Banchereau
Baylor University · USTexas Scottish Rite Hospital for Children · US

Funding

Targeting Dendritic Cells for Enhanced Musocal ImmunityU19AI057234 · NIAID · BAYLOR RESEARCH INSTITUTE · PI ZURAWSKI, GERARD · 2003 to 2013
$49.2M
SLAM Genes-from Mouse to ManP50AR055503 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI WANDSTRAT, AMY E · 2007 to 2011
$8.3M
Neutrophils in Lupus PathogenesisP50AR054083 · NIAMS · BAYLOR RESEARCH INSTITUTE · PI PASCUAL, MARIA VIRGINIA · 2006 to 2010
$6.2M
Use of Microarrays to Understand Systemic ArthritisR01AR050770 · NIAMS · BAYLOR RESEARCH INSTITUTE · PI PASCUAL, MARIA VIRGINIA · 2003 to 2012
$3.1M
SUBPOPULATIONS OF HUMAN DENDRITIC CELLSR01CA078846 · NCI · BAYLOR RESEARCH INSTITUTE · PI BANCHEREAU, JACQUES F · 1999 to 2008
$2.5M
Altered CD8+ T cell Compartment in SLE PatientsR01AI068842 · NIAID · BAYLOR RESEARCH INSTITUTE · PI BANCHEREAU, JACQUES F · 2006 to 2010
$1.8M
NCI NIH HHS CA78846NCI NIH HHS R01 CA078846NIAID NIH HHS AI068842NIAID NIH HHS R01 AI068842NIAID NIH HHS U19 AI057234NIAMS NIH HHS AR050770NIAMS NIH HHS AR054083NIAMS NIH HHS AR055503NIAMS NIH HHS P50 AR054083NIAMS NIH HHS P50 AR055503NIAMS NIH HHS R01 AR050770PHS HHS U19A1057234
6 · The paper itself

Abstract

summaryOur studies in children with rheumatic diseases have led to the identification of two of the oldest cytokines, type I interferon (IFN) and interleukin 1 (IL-1), as important pathogenic players in systemic lupus erythematosus (SLE) and systemic onset juvenile arthritis (SoJIA), respectively. These findings were obtained by studying the transcriptional profiles of patient blood cells and by assessing the biological and transcriptional effect(s) of active patient sera on healthy blood cells. We also identified a signature that can be used to promptly diagnose SoJIA from other febrile conditions. Finally, our pilot clinical trials using IL-1 blockers have shown remarkable clinical benefits in SoJIA patients refractory to other medications.

Indexed as

Gene Expression ProfilingAnimalsArthritis, JuvenileChildDiagnosis, DifferentialHumansImmunotherapyInterferon-alphaInterleukin-1Interleukin 1 Receptor Antagonist ProteinLupus Erythematosus, SystemicMiceInterferon-alphaInterleukin-1Interleukin 1 Receptor Antagonist Protein

Identifiers

PMID18613829
PMCPMC2753523
OpenAlexW2086209183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.